SARIN RAVI YANG
Known title: DirectorCIK: 0001555959
Associated companies
Transaction History
| STLN | ▲ Buy | Grant | 29,528 | $0 | 3/17/2023 | View on chart |
| STLN | ▲ Buy | Grant | 22,708 | $0 | 11/17/2022 | View on chart |
| STLN | ▲ Buy | Grant | 7,197 | $0 | 3/21/2022 | View on chart |
| STLN | ▲ Buy | Grant | 15,994 | $0 | 3/21/2022 | View on chart |
| STLN | ▲ Buy | Grant | 4,109,771 | $0 | 11/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Starling Oncology reports stronger cash flow and gross profit
Starling Oncology disclosed higher cash flow and gross profit in its latest results. The improvement has prompted analysts to consider a re‑rating of the stock. The company’s financial metrics are now better positioned relative to its recent price range.
Starling Oncology reports stronger cash flow and gross profit. Starling Oncology disclosed higher cash flow and gross profit in its latest results. The improvement has prompted analysts to consider a re‑rating of the stock. The company’s financial metrics are now better positioned relative to its recent price range.